Efficacy of Netarsudil in Open and Closed Angle Glaucomas Within the Vietnamese Population: A Single-Center, Retrospective Study

Purpose: To compare the intraocular pressure (IOP)–lowering efficacy and safety of netarsudil, a Rho-associated kinase (ROCK) inhibitor, among eyes with open-angle glaucoma (OAG), combined-mechanism glaucoma (CMG), and angle-closure glaucoma (ACG) in a predominantly Vietnamese population. Patients and Methods: A retrospective chart review was performed of eyes diagnosed with OAG, CMG, or ACG and treated with netarsudil (Rhopressa or Rocklatan) between 2018 and 2024 at a single glaucoma specialty clinic in San Jose, California. Baseline demographics, IOP, visual acuity, and cup-to-disc ratio were collected. The primary outcome was mean IOP reduction at 6 months. Secondary outcomes included discontinuation due to adverse effects and uncontrolled IOP requiring additional therapy or surgery. IOP values were adjusted using an estimated value for medication changes following ROCK inhibitor initiation. Mixed-effects linear regression and parametric survival models were used, adjusting for baseline covariates and IOP. Results: A total of 235 eyes were included: 116 with OAG, 66 with CMG, and 53 with ACG. The mean patient age was 74.9 ± 9.4 years, with 90% identifying as Vietnamese. Mean IOP reduction at 6 months was similar across groups (OAG: 4.2 ± 3.9 mmHg; CMG: 3.4 ± 4.1 mmHg; ACG: 4.3 ± 5.0 mmHg; p> 0.05). After adjustment for baseline IOP and covariates, no statistically significant differences were found. Discontinuation due to adverse effects occurred in 16% of OAG, 14% of CMG, and 8% of ACG eyes (p> 0.05), with conjunctival hyperemia most common. Rates of uncontrolled IOP were also similar among groups (p> 0.05). Conclusion: Netarsudil and its combination therapies demonstrated no significant difference in IOP reduction and tolerability across OAG, CMG, and ACG. These findings support its use as an adjunctive therapy regardless of angle configuration and highlight the need for prospective studies in Asian populations. Keywords: ROCK inhibitor, intraocular pressure, open-angle glaucoma, angle-closure glaucoma, combined-mechanism glaucoma

Authors

Institutions

Publication Details

Journal
Clinical ophthalmology
Published
2026-05-01
DOI
https://doi.org/10.2147/opth.s596749
Primary Topic
Glaucoma and retinal disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy of Netarsudil in Open and Closed Angle Glaucomas Within the Vietnamese Population: A Single-Center, Retrospective Study

Sunee Chansangpetch, Dzuy Truong, Kelly Nguyen, Sunita Radhakrishnan et al.
Clinical ophthalmology
Glaucoma and retinal disorders
article

Efficacy of Netarsudil in Open and Closed Angle Glaucomas Within the Vietnamese Population: A Single-Center, Retrospective Study

Sunee Chansangpetch, Dzuy Truong, Kelly Nguyen, Sunita Radhakrishnan, Shan Lin, Eden Ng, Ngoc Nguyen, Andrew Iwach
article en

Abstract

Purpose: To compare the intraocular pressure (IOP)–lowering efficacy and safety of netarsudil, a Rho-associated kinase (ROCK) inhibitor, among eyes with open-angle glaucoma (OAG), combined-mechanism glaucoma (CMG), and angle-closure glaucoma (ACG) in a predominantly Vietnamese population. Patients and Methods: A retrospective chart review was performed of eyes diagnosed with OAG, CMG, or ACG and treated with netarsudil (Rhopressa or Rocklatan) between 2018 and 2024 at a single glaucoma specialty clinic in San Jose, California. Baseline demographics, IOP, visual acuity, and cup-to-disc ratio were collected. The primary outcome was mean IOP reduction at 6 months. Secondary outcomes included discontinuation due to adverse effects and uncontrolled IOP requiring additional therapy or surgery. IOP values were adjusted using an estimated value for medication changes following ROCK inhibitor initiation. Mixed-effects linear regression and parametric survival models were used, adjusting for baseline covariates and IOP. Results: A total of 235 eyes were included: 116 with OAG, 66 with CMG, and 53 with ACG. The mean patient age was 74.9 ± 9.4 years, with 90% identifying as Vietnamese. Mean IOP reduction at 6 months was similar across groups (OAG: 4.2 ± 3.9 mmHg; CMG: 3.4 ± 4.1 mmHg; ACG: 4.3 ± 5.0 mmHg; p> 0.05). After adjustment for baseline IOP and covariates, no statistically significant differences were found. Discontinuation due to adverse effects occurred in 16% of OAG, 14% of CMG, and 8% of ACG eyes (p> 0.05), with conjunctival hyperemia most common. Rates of uncontrolled IOP were also similar among groups (p> 0.05). Conclusion: Netarsudil and its combination therapies demonstrated no significant difference in IOP reduction and tolerability across OAG, CMG, and ACG. These findings support its use as an adjunctive therapy regardless of angle configuration and highlight the need for prospective studies in Asian populations. Keywords: ROCK inhibitor, intraocular pressure, open-angle glaucoma, angle-closure glaucoma, combined-mechanism glaucoma

Clinical ophthalmologyVol. Volume 20
Chulalongkorn University (TH), University of California, San Francisco (US), King Chulalongkorn Memorial Hospital (TH), Piedmont University (US), Glaucoma Research Foundation (US), Saint Louis University (US)
Good health and well-being
Openalex Percentile: Top 5%
Glaucoma and retinal disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.